Gates Ventures

Lumotive develops optical semiconductor solutions that enhance sensing and perception capabilities across various industries. The company focuses on products such as the Light Control Metasurface beam steering chips, which facilitate advanced functionalities in mobile devices, autonomous vehicles, and robotics. These chips are designed for easy integration and provide a compact solution for applications requiring precise control of light. Lumotive’s technology supports a range of uses in consumer electronics, mobility, and industrial automation, enabling improved performance in sensing and imaging tasks.

Lumotive develops optical semiconductor solutions that enhance sensing and perception capabilities across various industries. The company focuses on products such as the Light Control Metasurface beam steering chips, which facilitate advanced functionalities in mobile devices, autonomous vehicles, and robotics. These chips are designed for easy integration and provide a compact solution for applications requiring precise control of light. Lumotive’s technology supports a range of uses in consumer electronics, mobility, and industrial automation, enabling improved performance in sensing and imaging tasks.

Vicarious Surgical is a next-generation robotics company developing a disruptive technology with the goal of increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. Vicarious Surgical aims to revolutionize the field of minimally invasive surgery by developing advanced robotic systems that allow surgeons to perform complex procedures with greater precision and control. The company's robotic system is designed to be compact and portable, enabling it to be easily integrated into existing operating rooms without significant modifications. The robot's design also aims to minimize the invasiveness of surgical procedures, leading to faster patient recovery times and reduced post-operative discomfort.

Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Mainspring designs and develops digital business strategies. The company provides consulting services focusing on digital technologies, business optimization, and technology enablement. Mainspring, formerly known as Mainspring Communications Inc., was founded in 1996 and is based in Cambridge, Massachusetts.